RBC reiterates CollaGenex at outperform

CollaGenex Pharmaceuticals Inc. was reiterated at outperform, speculative risk, and a $19 price target by RBC Capital Markets analyst Ken Trbovich. IMS Health weekly total prescriptions for Oracea increased 26% to 2,732 from 2,160. The analyst expects Oracea to beat his August prescription estimate of 3,000. The current 10,928 prescriptions per month run rate exceeds RBC's 8,000 prescription monthly estimate for September. Shares of the Newtown, Pa.-based specialty pharmaceutical company were up 37 cents, or 2.92%, at $13.06, on volume of 149,371 shares versus the three-month running average of 173,597 shares. (Nasdaq: CGPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.